Treatment of COVID-19 /  Tested positive (antigen) on day 12 after final dose of Paxlovid with mild symptoms: congestion/runny nose, dry cough, bleary eyes, body aches, fatigue, but no fever; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Treatment of COVID-19 /  Tested positive (antigen) on day 12 after final dose of Paxlovid with mild symptoms: congestion/runny nose, dry cough, bleary eyes, body aches, fatigue, but no fever) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044B21A, 017B21A and 026A21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (The patient had allergy to an unknown past drug).   On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Treatment of COVID-19 /  Tested positive (antigen) on day 12 after final dose of Paxlovid with mild symptoms: congestion/runny nose, dry cough, bleary eyes, body aches, fatigue, but no fever). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 13-May-2022 to 17-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Treatment of COVID-19 /  Tested positive (antigen) on day 12 after final dose of Paxlovid with mild symptoms: congestion/runny nose, dry cough, bleary eyes, body aches, fatigue, but no fever) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 29-May-2022, SARS-CoV-2 test: positive (Positive) Positive with mild symptoms.         No concomitant medications were reported. The patient tested negative (antigen) on day 5 after final dose of Paxlovid. Tested positive (antigen) on day 12 after final dose of Paxlovid with mild symptoms: congestion/runny nose, dry cough, bleary eyes, body aches, fatigue, but no fever. The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. Device Date was reported as 29-May-2022.  Company comment: This spontaneous case concerns a unspecified age and gender, with no relevant medical history reported, who experienced the unexpected non-serious AESI event of COVID-19 unspecified days after receiving third dose of mRNA-1273 vaccine. It was reported that patient was treated with Paxlovid from 13-may-2022 to 17-may-2022.Patient Tested negative 5 days after last dose of paxlovid later she started congestion/runny nose, dry cough,bleary eyes, body aches, fatigue. She was tested positive 12 days after the treatment with Paxlovid. The current pandemic situation of COVID 19 may remain as confounder to the event Covid-19.  The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a unspecified age and gender, with no relevant medical history reported, who experienced the unexpected non-serious AESI event of COVID-19 unspecified days after receiving third dose of mRNA-1273 vaccine. It was reported that patient was treated with Paxlovid from 13-may-2022 to 17-may-2022.Patient Tested negative 5 days after last dose of paxlovid later she started congestion/runny nose, dry cough,bleary eyes, body aches, fatigue. She was tested positive 12 days after the treatment with Paxlovid. The current pandemic situation of COVID 19 may remain as confounder to the event Covid-19.  The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.